- Previous Close
5,549.70 - Open
5,550.55 - Bid --
- Ask --
- Day's Range
5,535.00 - 5,681.45 - 52 Week Range
3,611.05 - 6,285.45 - Volume
316,859 - Avg. Volume
366,947 - Market Cap (intraday)
1.504T - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
72.92 - EPS (TTM)
77.70 - Earnings Date May 23, 2025 - May 27, 2025
- Forward Dividend & Yield 30.00 (0.54%)
- Ex-Dividend Date Aug 2, 2024
- 1y Target Est
5,917.38
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
www.divislabs.com9,741
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: DIVISLAB.NS
View MorePerformance Overview: DIVISLAB.NS
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DIVISLAB.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DIVISLAB.NS
View MoreValuation Measures
Market Cap
1.47T
Enterprise Value
1.44T
Trailing P/E
71.29
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.32
Price/Book (mrq)
10.74
Enterprise Value/Revenue
15.92
Enterprise Value/EBITDA
45.51
Financial Highlights
Profitability and Income Statement
Profit Margin
22.77%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
90.78B
Net Income Avi to Common (ttm)
20.67B
Diluted EPS (ttm)
77.70
Balance Sheet and Cash Flow
Total Cash (mrq)
36.02B
Total Debt/Equity (mrq)
0.06%
Levered Free Cash Flow (ttm)
--